Chikungunya Virus-Associated Disease
Purpose of Review
Chikungunya virus (CHIKV) infection has become increasingly prevalent in the last decade not only across the southern hemisphere but also, because of a recently documented viral mutation, in southern Europe and the USA. With the global spread of CHIKV infection, practitioners should know its epidemiology, pathophysiology and clinical features.
The acute phase of CHIKV disease is characterised by a fever–arthralgia–rash syndrome. Chronic rheumatic manifestations can persist for months to years with very variable clinical presentations. Some cases mimic inflammatory rheumatism such as rheumatoid arthritis. Several risk factors for persistent joint pain, notably older age, have been identified in cohort studies.
Despite a low mortality rate with CHIKV infection, the rate of disability with chronic joint symptoms is high, and effective treatments are lacking. Current research is focusing on the development of vaccines and antiviral drugs, and data on treatment of CHIKV-induced chronic arthritis are needed.
KeywordsChikungunya Infection-associated arthritis Arbovirus
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 22.Hoarau J-J, Jaffar Bandjee M-C, Krejbich Trotot P, et al. Persistent chronic inflammation and infection by chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Immunol Baltim Md 1950. 2010;184:5914–27.Google Scholar
- 24.Bouquillard E, Fianu A, Bangilo M, et al. Rheumatic manifestations associated with chikungunya virus infection: a study of 307 patients with 32-month follow-up (RHUMATOCHIK study). Joint Bone Spine. 2017. https://doi.org/10.1016/j.jbspin.2017.01.014.
- 28.Ng KW, Chow A, Win MK, et al. Clinical features and epidemiology of chikungunya infection in Singapore. Singap Med J. 2009;50:785–90.Google Scholar
- 40.Teo T-H, Lum F-M, Claser C, et al. A pathogenic role for CD4+ T cells during chikungunya virus infection in mice. J. Immunol. Baltim. Md 1950. 2013;190:259–69.Google Scholar
- 44.Differentiating chikungunya from dengue: a clinical challenge [Internet]. Medscape. [cited 2017 Jul 25]. Available from: http://www.medscape.com/viewarticle/831523.
- 45.Krutikov M, Manson J. Chikungunya virus infection: an update on joint manifestations and management. Rambam Maimonides Med J. 2016;7Google Scholar
- 47.Organization WH, Asia RO for S-E. Guidelines on clinical management of chikungunya fever. 2008 [cited 2017 Jul 30]; Available from: http://www.who.int/iris/handle/10665/205178.
- 52.Miner JJ, Cook LE, Hong JP, et al. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci Transl Med. 2017;9Google Scholar